Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mareike Verbeek

Showing results (61-70 of 61) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 61 results.
The Lancet. Haematology|October 14, 2019
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trialDietrich Wilhelm Beelen, Rudolf Trenschel, Matthias Stelljes, et al.
Pageof 7

Showing results (61-70 of 61) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 61 results.
The Lancet. Haematology|October 14, 2019
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trialDietrich Wilhelm Beelen, Rudolf Trenschel, Matthias Stelljes, et al.
Pageof 7